We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$133M
AUM Growth
-$14.8M
Cap. Flow
-$12.1M
Cap. Flow %
-9.06%
Top 10 Hldgs %
36.98%
Holding
83
New
24
Increased
11
Reduced
18
Closed
24

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.46M
2
ARVN icon
Arvinas
ARVN
+$5.31M
3
HUM icon
Humana
HUM
+$4.85M
4
SLNO
Soleno Therapeutics
SLNO
+$4M
5
RLAY icon
Relay Therapeutics
RLAY
+$3.64M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$6.55M
2
TGTX icon
TG Therapeutics
TGTX
+$4.86M
3
ALGN icon
Align Technology
ALGN
+$4.76M
4
CI icon
Cigna
CI
+$4.23M
5
BNTX icon
BioNTech
BNTX
+$4.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
2 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$2.39B
$575K 0.43%
+41,212
New +$727K
APRE icon
52
Aprea Therapeutics
APRE
$7.68M
$420K 0.32%
127,960
-9,214
-7% -$30.8K
AKBA icon
53
Akebia Therapeutics
AKBA
$354M
$391K 0.29%
+205,956
New +$358K
MDGL icon
54
Madrigal Pharmaceuticals
MDGL
$10.8B
$305K 0.23%
+987
New +$278K
CYPH
55
Cypherpunk Technologies Inc
CYPH
$62.9M
$295K 0.22%
102,631
– –
MRSN
56
DELISTED
Mersana Therapeutics
MRSN
$250K 0.19%
6,917
-40,226
-85% -$2.08M
NMRA icon
57
CALL
Neumora Therapeutics
NMRA
$298M
$207K 0.16%
+600
New +$7.19K
ABUS icon
58
Arbutus Biopharma
ABUS
$857M
$92.5K 0.07%
+28,300
New +$104K
ACRV icon
59
Acrivon Therapeutics
ACRV
$64.2M
– –
-116,757
Closed -$817K
ADAG
60
Adagene
ADAG
$248M
– –
-262,625
Closed -$583K
AGIO icon
61
Agios Pharmaceuticals
AGIO
$1.79B
– –
-66,200
Closed -$2.94M
ALGN icon
62
Align Technology
ALGN
$12.1B
– –
-18,700
Closed -$4.76M
AMGN icon
63
Amgen
AMGN
$208B
– –
-6,700
Closed -$2.16M
ASND icon
64
Ascendis Pharma A/S
ASND
$16B
– –
-43,849
Closed -$6.55M
BCRX icon
65
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-196,500
Closed -$1.49M
BIIB icon
66
Biogen
BIIB
$30B
– –
-13,317
Closed -$2.57M
BNTX icon
67
BioNTech
BNTX
$22.9B
– –
-34,552
Closed -$4.1M
CI icon
68
Cigna
CI
$73.7B
– –
-12,200
Closed -$4.23M
GKOS icon
69
Glaukos
GKOS
$9.83B
– –
-25,857
Closed -$3.37M
INSM icon
70
Insmed
INSM
$21.4B
– –
-33,600
Closed -$2.45M
KURA icon
71
Kura Oncology
KURA
$800M
– –
-90,305
Closed -$1.76M
LXEO icon
72
Lexeo Therapeutics
LXEO
$324M
– –
-88,148
Closed -$797K
PACB icon
73
Pacific Biosciences
PACB
$435M
– –
-75,300
Closed -$128K
QTRX icon
74
Quanterix
QTRX
$164M
– –
-73,501
Closed -$953K
RZLT icon
75
Rezolute
RZLT
$454M
– –
-352,056
Closed -$1.71M
1 2
3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Exome Asset Management held 83 positions worth $133M, down 10% from $148M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Exome Asset Management withdrew a net $12.1M in Q4 2024, closing 24 positions and reducing 18 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $6.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Exome Asset Management opened a new position in Syndax Pharmaceuticals worth $4.22M.

  • Exome Asset Management's largest Q4 2024 buy was Syndax Pharmaceuticals: 318,900 shares worth $4.22M.
  • Exome Asset Management added most to Relay Therapeutics in Q4 2024, an estimated $3.64M increase.
  • Exome Asset Management's biggest Q4 2024 reduction was Mersana Therapeutics, cutting an estimated $2.08M.
  • Exome Asset Management fully exited Ascendis Pharma A/S in Q4 2024, selling an estimated $6.55M.
  • Exome Asset Management's ten largest holdings make up 37% of its $133M portfolio in Q4 2024.
  • Exome Asset Management opened 24 new positions and closed 24 in Q4 2024.
  • Exome Asset Management's portfolio value fell 10% quarter-over-quarter to $133M.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.